Highly Speculative and High Risk Stocks ( GCI, LTD, NKTR, DXCM )

Los Angelas, CA -- (SBWIRE) -- 09/21/2012 -- Gannett Co., Inc. (NYSE:GCI) is +0.45 - +2.46% from the previous close of $18.29. It traded between $18.15 - 19.09 with total traded volume of 10390588 shares. Keep a close eye on GCI, as the stock has been showing unusual moves over the past weeks. At Current market price, GCI has recovered +120.99% from its 52-week Low of 8.48 and has Pulled back -1.83% from its 52-week high of 19.09. Gannett Co., Inc.(NYSE:GCI) shares climbed 4.34% and closed at $18.29 in the previous trading session. Equities research analysts at UBS AG boosted their price target on shares of Gannett to $18.00 in a research note issued to investors this week. Additionally, CareerBuilder announced it has acquired Economic Modeling Specialists Intl. (EMSI), an economic software firm that specializes in employment data and labor market analysis. CareerBuilder is owned by Gannett Co Inc, Tribune Company and The McClatchy Company. The terms of the acquisition were not disclosed.

Get A Free Analysis Report On GCI : CLICK HERE

Limited Brands, I (NYSE:LTD) is +1.75 - +3.50% from the previous close of $50.00. It traded between $50.03 - 51.82 with total traded volume of 3946457 shares. Keep a close eye on LTD, as the stock has been showing unusual moves over the past weeks. At Current market price, LTD has recovered +40.13% from its 52-week Low of 36.93 and has Pulled back -0.17% from its 52-week high of 51.84. Limited Brands (LTD) was upgraded by analysts at Credit Suisse on Wednesday to Outperform from Neutral. Analysts noted that the company has strong pricing power and has an opportunity to expand its businesses into overseas markets. Credit Suisse issued a $59 price target for LTD, which represents a significant premium to Tuesday’s closing price of $50. Limited Brands operates several retail companies, including Victoria’s Secret, Bath & Body Works, and Pink. The stock has performed well so far in 2012, gaining about 23% year-to-date.

Get A Free Analysis Report On LTD : CLICK HERE

Nektar Therapeuti (NasdaqNM:NKTR) is +0.48 - +4.99% from the previous close of $9.62. It traded between $9.574 - 10.20 with total traded volume of 2101487 shares. At Current Market Price, NKTR is in distance of +18.03% from its 50-day Moving Average price of $8.5569 and +27.46% from its 200-day Moving Average price of $7.924. Nektar Therapeutics (NKTR:Quote) Tuesday announced that the positive results from the first single-ascending dose Phase 1a clinical study of NKTR-192 demonstrate that the drug candidate achieved its target pharmacokinetic profile. The company also announced that dosing has commenced in a second single-ascending dose Phase 1a clinical study of NKTR-192, which will explore the pharmacodynamic profile of this new drug candidate in healthy subjects. The second Phase 1a clinical study will assess the pharmacodynamic profile and tolerability of single ascending doses of NKTR-192 in up to 48 healthy subjects. "Results from our first clinical study of NKTR-192 demonstrated that this new mu-opioid molecule achieved a short-acting pharmacokinetic profile which is ideal for the treatment of acute pain," said Robert Medve, M.D., Chief Medical Officer of Nektar Therapeutics.

Get A Free Analysis Report On NKTR : CLICK HERE

DexCom, Inc. (NasdaqNM:DXCM) is +0.45 - +3.15% from the previous close of $14.28. It traded between $14.26 - 14.82 with total traded volume of 623882 shares. At Current Market Price, DXCM is in distance of +13.30% from its 50-day Moving Average price of $13.0009 and +27.58% from its 200-day Moving Average price of $11.5461. First Analysis downgraded shares of DexCom from an “overweight” rating to an “equal weight” rating in a research note to investors on Friday, September 14th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note to investors on Friday, August 24th. They now have a $13.00 price target on the stock. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of DexCom in a research note to investors on Friday, June 22nd.

Get A Free Analysis Report On DXCM : CLICK HERE

Disclaimer:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com